Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disorder (estimated prevalence of 1 per 1000–1 per 2500 live births)1 characterized by the development and growth of multiple bilateral cysts eventually leading to end-stage renal disease and renal replacement therapy.1